Abstract: In one embodiment, carbon dioxide is converted into a chemical feedstock by providing a mixture of plasmonic material and oxygen-conducting material, exposing the mixture to sunlight so that solar energy is absorbed by the plasmonic material which then heats the oxygen-conducting material so that oxygen vacancies are generated, passing carbon dioxide through the mixture, and the oxygen-conducting material removing oxygen atoms from the carbon dioxide to form carbon monoxide.

Abstract: A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy.